Background: Ridge resorption following tooth extraction may be reduced by alveolar ridge preservation (ARP). Previous randomized clinical trials and systematic reviews have suggested that autogenous tooth bone graft (ATB) can be an effective alternative material for ARP. However, the results are heterogeneous. Therefore, our research aimed to evaluate the efficacy of ATB in ARP. Methods: A systematic search was conducted in Cochrane Library, Embase, MEDLINE and Scopus for studies published from inception to 31 November 2021. We searched searched for randomized, non-randomized controlled trials and case series reporting on ATB use for ARP. The primary outcome was the ridge width difference pre- and post-surgery, measured in millimetres (mm) measured on CBCT (cone beam computed tomography). The secondary outcomes were the histological results. We followed the PRISMA2020 recommendations for reporting our systematic review and meta-analysis. Results: The analysis included eight studies for the primary and six for the secondary outcomes. The meta-analysis revealed a positive ridge preservation effect with a pooled mean difference ridge width change of -0.72 mm. The pooled mean residual graft proportion was 11.61%, and the newly formed bone proportion was 40.23%. The pooled mean of newly formed bone proportion was higher in the group where ATB originated from both the root and crown of the tooth. Conclusions: ATB is an effective particulate graft material in ARP. Complete demineralization of the ATB tends to decrease the proportion of newly formed bone. ATB can be an attractive option for ARP. Trial registration: The study protocol was registered on PROSPERO (CRD42021287890).

Background/Objectives: During alveolar cleft grafting, the use of autogenous cancellous bone harvested from the iliac crest is still considered the gold standard. Due to the risk of donor-site morbidity and excessive graft resorption, alternative grafting materials (e.g., intraoral bone, xenografts) are being tested. The aim of this study was to compare the efficacy of using an autologous tooth-derived graft material and iliac crest cancellous bone in the reconstruction of the alveolar cleft in patients with a unilateral cleft lip and palate. Methods: A total of 21 patients with a unilateral cleft lip and palate, who underwent alveolar bone grafting between 2020 and 2023 were included in the study. In 11 cases, the donor site was the iliac crest; in the rest of the cases, deciduous teeth were harvested, processed, and used as an autologous particulate graft material for alveolar reconstruction. The mean follow-up time was 30.0 months, CBCT scans were taken, and the results were compared based on the ranking system published by Stasiak et al. Results: The Wilcoxon signed-rank test showed that the amount of bone on the cleft side was significantly less than that on the contralateral non-cleft side (ATB: p = 0.002, iliac crest: p = 0.005). The Mann–Whitney U test showed that there were no significant differences in bone quantity on the cleft side between the two groups (U = 47.5, p = 0.617). Conclusions: The use of ATB might be a feasible alternative to autologous bone during alveolar cleft reconstruction. This type of graft shows long-term stability, which is comparable to the bone harvested from the iliac crest.

A retrospektív esetsorozat célja intraosszeális csontdefektusok gyógyulásának hosszú távú klinikai értékelése autológ vérlemezkében gazdag készítménnyel (Platelet-Rich Gel, PRG) vagy zománc-mátrix derivátummal (Enamel Matrix Derivatives, EMD) történt kezelést követően. A vizsgálatban 24 intraosszeális defektussal rendelkező, nem dohányzó, krónikus parodontitisben szenvedő páciens vett részt. A négy bemutatott eset ezen kontrollált klinikai vizsgálat résztvevője, akiknél 1, 3, illetve 7 évvel a műtétet követően történt kiértékelés a következő paraméterek rögzítésével: szondázási mélység (PD – probing depth), illetve klinikai tapadási szint (CAL – clinical attachment level). Teljes vastagságú lebenyek képzését követően a defektus kürettálása, illetve gyökérsimítás történt. Vérlemezkében gazdag plazma (PRP) preparálása után, Ca-glükonát és friss vénás vér hozzáadásával vérlemezkében gazdag plazma gél (PRG) készült. A parodontális vertikális defektusok ellátását PRG (n = 2) vagy EMD (n = 2) applikációját követően sebzárás követte. Egy évvel a műtét után mindkét kezelési módszer szignifikáns szondázási mélység (PD) csökkenést és klinikai tapadási nívó (CAL) növekedést eredményezett, és ezek az eredmények 3, illetve 7 év után is kedvezőek maradtak. Bemutatott eseteinknél, úgy a PRG-, mint az EMD-kezelés megbízható hosszú távú klinikai eredményeket mutatott.

Background: The predictability of regenerative outcomes in non-contained intrabony periodontal defects remains limited. Autogenous tooth bone grafts (ATB) may represent a biologically active and osteoconductive scaffold with minimal residual graft material. This study evaluated the clinical and radiographic outcomes of ATB combined with enamel matrix derivative (EMD) in intrabony defects. Methods: Nine systemically healthy patients (15 defects) were treated with ATB + EMD in a retrospective proof-of-concept design. Clinical parameters—probing pocket depth (PPD), clinical attachment level (CAL), and gingival recession (GR)—were recorded at baseline and 6 months. Radiographic changes in defect depth and width were also assessed. Statistical significance was set at p < 0.05. Results: Mean PPD decreased from 7.73 ± 0.96 mm to 3.87 ± 0.74 mm (p < 0.001), and CAL improved from 9.20 ± 1.47 mm to 5.53 ± 1.36 mm (p < 0.001). GR changes were not significant. Radiographically, mean defect depth and width were reduced from 3.81 ± 1.59 mm and 2.56 ± 0.75 mm to 0.72 ± 1.08 mm and 0.44 ± 0.70 mm, respectively (p < 0.001). Conclusions: The combination of ATB and EMD yielded substantial clinical and radiographic improvements in intrabony periodontal defects. These findings suggest that autogenous tooth bone grafts may serve as a reliable biologically active scaffold for regenerative periodontal surgery. This is the first study evaluating the combination of EMD and ATB. Within the study limitations, ATB + EMD demonstrated promising regenerative potential, warranting future controlled clinical trials.

Background: Periodontal regenerative surgery is a well-established treatment modality for intrabony periodontal defects. Enamel matrix derivative (EMD) is one of the most extensively documented biologic agents, whereas platelet-rich fibrin (PRF) has emerged as a promising autologous alternative. This prospective randomized controlled clinical study aimed to compare the long-term clinical outcomes of PRF and EMD in the treatment of periodontal intrabony defects. Methods: Thirty patients with periodontitis Stage III/IV, grade B/C and at least one intrabony defect [probing pocket depth (PPD) ≥ 6 mm; intrabony component ≥ 4 mm] were randomly assigned to surgery using PRF (test group) or EMD (control group). The primary outcome was clinical attachment level (CAL) gain. Secondary outcomes included PPD reduction, gingival recession (GR), and bone sounding (BS) changes. Clinical parameters were recorded at baseline, 6 months, and 3 years postoperatively. Intergroup comparisons of mean clinical changes were performed using appropriate parametric and nonparametric statistical tests (α = 0.05). Results: Twenty-six patients completed the 3-year follow-up. Both treatment modalities resulted in significant clinical improvements that remained stable over time. At 6 months, mean PPD reduction was 4.40 ± 2.44 mm in the PRF group and 3.53 ± 2.67 mm in the EMD group, while mean CAL gain measured 3.87 ± 2.20 mm and 2.13 ± 2.80 mm, respectively. GR increase was lower in the PRF group compared with the EMD group (0.53 ± 1.13 mm vs. 1.40 ± 1.45 mm), although the difference did not reach statistical significance ( p = 0.079). At 3 years, mean PPD reduction was 3.69 ± 1.70 mm in the PRF group and 3.31 ± 3.45 mm in the EMD group, while CAL gain measured 3.77 ± 1.48 mm and 2.54 ± 3.62 mm, respectively. A significantly lower increase in GR was observed in the PRF group compared with the EMD group at 3 years (− 0.08 ± 0.64 mm vs. 0.77 ± 1.30 mm; p = 0.046). No statistically significant intergroup differences were detected for PPD reduction, CAL gain, or BS reduction. Conclusions: PRF and EMD provided comparable and stable long-term clinical improvements following regenerative periodontal surgery of intrabony defects. PRF may represent a reliable autologous alternative to EMD in periodontal regenerative therapy. Trial registration: ClinicalTrials.gov registration number NCT07183631 retrospectively registered, 14/09/2025.